ESMO 2018

Conference Correspondent | October 22, 2018
Fatigue and neuropathy were found to be common in patients treated with olaparib, and should be identified and managed early.
Conference Correspondent | October 22, 2018
The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity.
Conference Correspondent | October 22, 2018
Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established.
Conference Correspondent | October 21, 2018
Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation.
Conference Correspondent | October 21, 2018
Progression-free survival associated with rucaparib is not affected by the number of prior chemotherapy regimens.
Conference Correspondent | October 21, 2018
Results from the phase 3 SOLO1 trial demonstrate a substantial, unprecedented improvement in progression-free survival for olaparib versus placebo.
Conference Correspondent | October 21, 2018
This combination of antiangiogenic and immune checkpoint blockade has clinical activity in women with recurrent ovarian cancer.
Conference Correspondent | October 21, 2018
Results from the KEYNOTE-100 study show that expression of PD-L1 and inflamed T-cell–associated genes are associated with clinical response in advanced, recurrent ovarian cancer.-->
Conference Correspondent | October 20, 2018
Durvalumab/PLD combination shows promising efficacy and a tolerable safety profile in women with platinum-resistant ovarian cancer.
Conference Correspondent | October 20, 2018
Olaparib maintenance may prolong progression-free survival in patients, regardless of the number of previous platinum-based chemotherapies.
Page 1 of 2
Results 1 - 10 of 18

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code